Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | CHUK | O15111 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | PIM1 | P11309 | 1/20 | 0.39 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.39 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29870952 | 0.85 | KDM4C (0.43) | CA1CA2CA9CHUKTSHR | |
| SCHEMBL26426466 | 0.85 | KDM4C (0.43) | CA1CA2CA9CHUKTSHR | |
| SCHEMBL6774875 | 0.83 | KDM4C (0.42) | CA1CA2CA9ALDH1A1KDM4C | |
| SCHEMBL10338664 | 0.82 | KDM4C (0.47) | CHUKTSHRDYRK1AALDH1A1HPGD | |
| SCHEMBL9426430 | 0.81 | KDM4E (0.50) | CHUKALDH1A1KDM4CKMT2AMEN1 | |
| SCHEMBL8688740 | 0.81 | MDM4 (0.45) | GAAMAPT | |
| SCHEMBL3899443 | 0.81 | TSHR (0.48) | CA1CA2CA9TSHRKDM4E | |
| SCHEMBL4139383 | 0.79 | ALDH1A1 (0.55) | CHUKTSHRDYRK1AALDH1A1HPGD | |
| SCHEMBL9017873 | 0.79 | MAPT (0.52) | CA1CA2CA9CHUKTSHR | |
| SCHEMBL16305298 | 0.78 | CA1 (0.46) | CA1CA2CA9CHUKTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577242-B2 | Pyrrolopyridine and imidazopyridine antiviral compounds | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2026-03-17 | — | — | US | disclosed |
| US-20230130598-A1 | PYRROLOPYRIDINE AND IMIDAZOPYRIDINE ANTIVIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-04-27 | — | — | US | disclosed |
| US-20230130598-A1 | PYRROLOPYRIDINE AND IMIDAZOPYRIDINE ANTIVIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-04-27 | — | — | US | disclosed |
| US-20230130598-A1 | PYRROLOPYRIDINE AND IMIDAZOPYRIDINE ANTIVIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-04-27 | — | — | US | disclosed |
| EP-4110777-A1 | PYRROLOPYRIDINE AND IMIDAZOPYRIDINE ANTIVIRAL COMPOUNDS | Katholieke Universiteit Leuven, K.U.Leuven R&D (BE) | 2023-01-04 | — | — | EP | disclosed |
| CN-115175909-A | Pyrrolopyridine and imidazopyridine antiviral compounds | 鲁汶天主教大学 | 2022-10-11 | — | — | CN | disclosed |
| US-RE45173-E1 | Inhibitors of CYP 17 | NOVARTIS AG (CH) | 2014-09-30 | — | — | US | disclosed |
| US-20140228394-A1 | INHIBITORS OF CYP 17 | NOVARTIS AG (CH) | 2014-08-14 | — | — | US | disclosed |
| EP-2445903-B1 | 1,3-DISUBSTITUTED IMIDAZOLIDIN-2-ONE DERIVATIVES AS INHIBITORS OF CYP 17 | NOVARTIS AG (CH) | 2014-03-26 | — | — | EP | disclosed |
| CN-102803250-A | 1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of CYP17 | NOVARTIS AG | 2012-11-28 | — | — | CN | disclosed |
| US-8263635-B2 | Inhibitors of CYP 17 | NOVARTIS AG (CH) | 2012-09-11 | — | — | US | disclosed |
| US-20100331326-A1 | Inhibitors of CYP 17 | NOVARTIS AG | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331326-A1 | Inhibitors of CYP 17 | CYP17A1, CYP21A2, CYP4A22 | CA1 2451/4885CA2 2411/4885CA9 1824/4885 |
| US-20140228394-A1 | INHIBITORS OF CYP 17 | CYP17A1, CYP21A2, CYP4A22 | CA1 2451/4885CA2 2411/4885CA9 1824/4885 |
| US-20230130598-A1 | PYRROLOPYRIDINE AND IMIDAZOPYRIDINE ANTIVIRAL COMPOUNDS | SARS1, TPI1, TPMT | CA1 3049/4885CA2 1782/4885CA9 4278/4885 |
| US-12577242-B2 | Pyrrolopyridine and imidazopyridine antiviral compounds | SARS1, TPMT, ZC3HAV1 | CA1 3509/4885CA2 2731/4885CA9 1813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.